Background: For more than three decades, it has been known that manipulation of dopaminergicsystem could affect glucose homesotasis in experimental animals. The notion that glucosehomeostasis in human might be influenced by dopaminergic drugs has attracted a great deal of attentionin the past two decades. In spite of rapid advancements in revealing involvement of dopaminergic neurotransmissionin insulin release, glucose up-take and pancreatic beta cell function in general throughcentrally and peripherally controlled mechanisms, there are discrepancies among observations on experimentalanimals and human subjects.Conclusion: With the expansion of pharmacotherapy in psychotic conditions, depression and endocrineabnormalities along with a sharp increase in prevalence of type two diabetes and disturbances of glucosehomeostasis as a major risk factor for many cardiovascular complications and associated mortalities;it seems a critical analysis of recent investigations on drugs which act as agonists or antagonists ofdopaminergic receptors in various tissues and organs may provide better insight into how safe and efficientthese medicines could be prescribed. Furthermore, the other main objective of present review is tocompare clinical data on significance of changes in blood glucose and insulin levels during short termand after long term treatment with these agents. This in turn would be beneficial for determining adequatestrategies to combat or to avoid adverse effects associated with dopaminergic drug therapy.
展开▼
